{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:17:45Z","timestamp":1777670265910,"version":"3.51.4"},"reference-count":64,"publisher":"SAGE Publications","issue":"17-18","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>The recent success of first central nervous system gene therapies has reinvigorated the growing community of gene therapy researchers and strengthened the field's market position. We are witnessing an increase of clinical trials with long-term efficiency mainly for neurometabolic, neurodegenerative, and neurodevelopmental diseases caused by loss-of-function mutations. The ever-expanding knowledge and accessibility to the most advanced tools allow enrichment of applications to more complex diseases. This gradually contributes toward sealing the gap between top diseases impacting current global health and those toward which gene therapy development is currently aimed. In this study, we highlight innovative therapeutic approaches that have reached the clinics and outline the latest improvements of vector design and targeting. Finally, we address the pressing challenges faced by clinical trials and the direction they are heading.<\/jats:p>","DOI":"10.1089\/hum.2022.177","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T14:50:23Z","timestamp":1662562223000},"page":"913-922","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Central Nervous System Gene Therapy: Present Developments and Emerging Trends Accelerating Industry-Academia Pathways"],"prefix":"10.1177","volume":"33","author":[{"given":"Margareta","family":"Rybarikova","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences (DNC), Laboratory of Cellular and Molecular Neurotherapies (LCMN), Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne Switzerland"},{"name":"Neuroscience Research Center (CRN), Laboratory of Cellular and Molecular Neurotherapies (LCMN), Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Almacellas-Barbanoj","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Epilepsy (DCEE), University College London (UCL), Institute of Neurology (IoN), London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Schorge","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Epilepsy (DCEE), University College London (UCL), Institute of Neurology (IoN), London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4475-9476","authenticated-orcid":false,"given":"Nicole","family":"D\u00e9glon","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences (DNC), Laboratory of Cellular and Molecular Neurotherapies (LCMN), Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne Switzerland"},{"name":"Neuroscience Research Center (CRN), Laboratory of Cellular and Molecular Neurotherapies (LCMN), Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.110"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-00694-0"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-181331"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-018-07644-y"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.10.017"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.66"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0617-491"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1525\/2\/emmm.201707573"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1639"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S231804"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-092818-015530"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19505-2"},{"key":"e_1_3_5_14_2","unstructured":"Gene Therapy Market Size & Share Report 2021\u20132028; n.d. Available from: https:\/\/www.grandviewresearch.com\/industry-analysis\/gene-therapy-market [Last accessed: June 24 2022]."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1700554"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171242"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2018.081"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-020-00778-1"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300004"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01664-4"},{"key":"e_1_3_5_21_2","unstructured":"Trad M Aiach K Deneux M et al. A Study of Intracisternal Administration of LYS-GM101 in Children with Infantile GM1 Gangliosidosis: Preliminary Results of the Safety Cohort [abstract]. In: 2022 American Society of Gene & Cell Therapy Annual Meeting; May 16\u201319; Washington DC; 2022. Abstract nr 643."},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.238"},{"key":"e_1_3_5_23_2","unstructured":"Lysogene. Lysogene provides additional update on AAVance Phase 2\/3 Gene Therapy Clinical Trial with LYS-SAF302 in Children with MPS IIIA\u2014Lysogene; n.d. Available from: https:\/\/www.lysogene.com\/lysogene-provides-additional-update-on-aavance-phase-2-3-gene-therapy-clinical-trial-with-lys-saf302-in-children-with-mps-iiia\/ [Last accessed: August 31 2022]."},{"key":"e_1_3_5_24_2","unstructured":"Hiugliani R Escolar M Ficicioglu C et al. RGX-121 Gene Therapy for the Treatment of Severe Mucopolysaccharidosis Type II (MPS II): Interim Analysis of Data from the First in Human Study [abstract]. In: 2022 American Society of Gene & Cell Therapy Annual Meeting; May 16\u201319; Washington DC; 2022. Abstract nr 52."},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0138-8"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5413"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.135"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c29356"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012952"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25450"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.11.005"},{"key":"e_1_3_5_32_2","unstructured":"Bailey RM Armao D Garza I et al. Vagus Nerve Delivery of AAV9 to Treat Autonomic Nervous System Dysfunction in Giant Axonal Neuropathy [abstract]. In: 2022 American Society of Gene & Cell Therapy Annual Meeting; May 16\u201319; Washington DC; 2022. Abstract nr 3."},{"key":"e_1_3_5_33_2","unstructured":"Communications BA. BrainVectis a Subsidiary of AskBio Receives Clearance to Conduct Phase I\/II Clinical Trial in France for Its Novel Gene Therapy for Early-Stage Huntington's Disease; n.d. Available from: http:\/\/media.bayer.com\/baynews\/baynews.nsf\/id\/BrainVectis-a-subsidiary-AskBio-receives-clearance-conduct-Phase-I-II-clinical-trial-France-novel [Last accessed: August 31 2022]."},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-019-00731-6"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.809118"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674021"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.12.010"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2018.09.004"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1910061116"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-00793-4"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw2900"},{"key":"e_1_3_5_42_2","unstructured":"Nonnenmacher ME Ren AZ Wang W et al. Directed Evolution of an AAV5 Capsid Library Identifies a Variant with Enhanced Transduction in Non-Human Primate and Rodent Brain Following Systemic Administration [abstract]. In: 2022 American Society of Gene & Cell Therapy Annual Meeting; May 16\u201319; Washington DC; 2022. Abstract nr 129."},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.07.019"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.154"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.07.006"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66778"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac6191"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep13104"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.09.131"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.4238\/gmr.15038560"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-0169-1"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab182"},{"key":"e_1_3_5_53_2","unstructured":"Sadhu C Tetens S Flora G et al. A Human-Ready Regulated AAV9\/MiniMECP2-MiRARE Gene Therapy (TSHA-102) Improves Survival and Respiratory Health After Dosing Translationally Relevant Treatment Ages in Mice Modeling Rett Syndrome (RTT) [abstract]. In: 2022 American Society of Gene & Cell Therapy Annual Meeting; May 16\u201319; Washington DC; 2022. Abstract nr 644."},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2013.06.022"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2022.03.010"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00004-6"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2021.100353"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.06.058"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.27.20220871"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01481-9"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-020-00223-x"},{"key":"e_1_3_5_62_2","unstructured":"Potential Fabrication in Research Images Threatens Key Theory of Alzheimer's Disease; n.d. Available from: https:\/\/www.science.org\/content\/article\/potential-fabrication-research-images-threatens-key-theory-alzheimers-disease [Last accessed: August 31 2022]."},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/acem.13698"},{"issue":"4","key":"e_1_3_5_65_2","first-page":"39","article-title":"CGRP inhibitors for migraine","volume":"17","author":"Mohanty D","year":"2020","unstructured":"Mohanty D, , Lippmann S. CGRP inhibitors for migraine. Innov Clin Neurosci, 2020; 17(4\u20136):39\u201340.","journal-title":"Innov Clin Neurosci"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2022.177","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2022.177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2022.177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:15Z","timestamp":1777449375000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2022.177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":64,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1089\/hum.2022.177"],"URL":"https:\/\/doi.org\/10.1089\/hum.2022.177","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}